TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intra-arterial Measurement of pO2 in Walking Induced Transient Hack Profiles

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* walking induced transient Hack (WITH) tcpO2 profile~Exclusion Criteria:~* rejection by patient

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with walking limitation (Type: OTHER): Patients with claudication and Walking-Induced Transient Hack (W.I.T.H.) tcpO2 profiles are tested on treadmill with invasive pO2 arterial sampling and body temperature recording

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Nutritional Tolerance and Safety of a Tube Feeding Formula

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Medically stable, enterally tube-fed adults with a feeding tube diameter of at least 8 French OR medically stable, adults assessed to require enteral feeding initiation with a feeding tube diameter of at least 8 French (2.6 mm).~2. Aged 18 years or older at the time of screening visit.~3. Currently tolerating or determined to tolerate enteral feeding and eligible for feeding with a 1.5 kcal/mL formula, as per PI discretion.~4. Requires or will require enteral tube feeding to provide 90% or more of their daily nutritional needs without the use of modular(s) for at least 14 days.~5. Participant or their Legally Authorized Representatives (LAR) is willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary informed consent (or assent, if capable), carry out all study-related procedures, and communicate effectively with the study staff.~Exclusion Criteria:~1. Has a condition which contraindicates enteral feeding (e.g., intestinal obstruction).~2. Currently using the study formula~3. Any medical condition or contraindicated medications deemed exclusionary by the PI as determined by medical/medication history at the time of screening visit.~4. Any condition, in the opinion of the PI, that would contraindicate use of the study formula (e.g., need for severe fluid restriction, allergy to formula ingredients, etc.).~5. Participation in another interventional clinical study between 30 days prior to screening visit until the end of study.~6. Any condition or abnormality that, in the opinion of the QI, would compromise the safety of the participant or the quality of the study data.~7. Unable to obtain informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enteral Nutrition (EN) Formula (Type: EXPERIMENTAL): Enteral formula

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of COVID-19 Treatment Efficacy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* test positive for COVID-19~* be inpatient~* Have signs of respiratory distress = had either an SpO2 of less 95% or lower recorded or a respiratory rate RR \>20 (21 or more) recorded and \<60 (eliminate aberrant charting)~Exclusion Criteria:~* Age less than 18~* Currently actively in an investigational drug trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine - NO (Type: None): Did not receive / are not receiving any Hydroxychloroquine
- Hydroxychloroquine - YES - started before (Type: None): Hydroxychloroquine date started was before the date recorded for signs of respiratory distress
- Hydroxychloroquine - YES - started same (Type: None): Hydroxychloroquine date started was the same as the date recorded for signs of respiratory distress
- Hydroxychloroquine - YES - started after (Type: None): Hydroxychloroquine date started was after the date recorded for signs of respiratory distress

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prokinecitine in Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute St elevation myocardial infarction of less than 6 hours~* Age\>18 y/o~Exclusion Criteria:~* Previous myocardial infarction~* LBB, RBB~* Renal Insuffiency MDRD\<30 mL/min~* Patient with Pace-Maker or ICD.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 2 Doses of Mannitol on Post Traumatic Intracranial Hypertension and Cerebral Monitoring

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults~* severe traumatic brain injury~* intracranial hypertension requiring mannitol administration~Exclusion Criteria:~* impeding neurosurgery~* hemodynamic or respiratory severe failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- mannitol high dose (Type: ACTIVE_COMPARATOR): mannitol 20% 0,8 g/ kg on minutes
- mannitol low dose (Type: ACTIVE_COMPARATOR): mannitol 20% 0,4 g/ kg on minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Heart Rate Variability and Stress Management Enhancement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Neurosurgical Resident (UPMC)~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Biostrap/Apollo Device Use (Type: OTHER): Participants wear a Biostrap wearable device which measures steps, heart rate, heart rate variability, sleep metrics, and quantitative data in typical day-to-day activities of residents. Participants then again wear Biostrap except now also with the Apollo device which is worn around the ankle and is suggested to modulate heart rate variability and perceived stress of participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: BNT001 Digital Therapeutic Feasibility Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis or history of invasive cancer (excluding non-melanoma skin cancer).~* Patients showing mild to moderate anxiety or depression on the Veteran System Assessment Screen (VSAS), with anxiety or depression scored as 1-6 on a 0-10 scale.~* Fluent in English.~* Has access to iOS or Android smartphone, or tablet and capable of receiving text messages.~* Has an e-mail address.~Exclusion Criteria:~* Endorses thoughts of self-harm, history of suicidality.~* Currently participating in investigative behavioral intervention trial for treatment of anxiety or depression.~* Participant is unable to complete training, has cognitive deficits, major psychiatric conditions, psycho-social conditions; lack of access to reliable internet and accessible device; other social conditions that would interfere with adherence to self directed care, such that in investigator's opinion the participant would be unable to complete the study.~* Recently completed use of Blue Note Therapeutics COVID Cancer Care Program or other Blue Note Therapeutics sponsored study.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BNT001 (Type: EXPERIMENTAL): BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patient-Reported Outcome Measures in Cardiac Rehabilitation: Impact on Health Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (\> 18 years);~* Low-moderate risk for physical exercise;~* After a cardiac event;~* Have signed an informed consent form.~Exclusion Criteria:~* Physical or mental limitation to carry out an exercise programme;~* Uncontrolled arrhythmia;~* Severe chronic obstructive pulmonary disease;~* Uncontrolled hypertension;~* Symptomatic peripheral arterial disease;~* Unstable angina;~* Uncontrolled diabetes;~* Acute pulmonary oedema in the last 12 hours;~* Those who refuse to participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cardiac Rehabilitation intervention (Type: EXPERIMENTAL): Outpatient intervention with participants after a cardiac event who fulfil the inclusion criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Must be followed by the Inova Fairfax Hospital transplantation program for post-transplant care~2. Diabetes mellitus inadequately responsive to lifestyle modification and non-insulin hypoglycemic medication~3. Need for subcutaneous insulin therapy (after discontinuation of IV insulin therapy, if it was required)~4. Ability to read consent form and give consent in English.~Exclusion Criteria:~1. Use of insulin or non-insulin hypoglycemic medication before transplantation~2. Cystic fibrosis patients~3. Age \< 18 years of age~4. Pregnancy~5. Non-English speaking subjects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- insulin isophane (Type: ACTIVE_COMPARATOR): daily dose will be titrated based on fasting morning glucose values
- insulin glargine (Type: ACTIVE_COMPARATOR): daily dose will be titrated based on fasting morning glucose values

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of the Timing of Trigger on IVF Success

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planning to move forward with an IVF cycle~* Have met the requirements of being a patient at CCRM Colorado~* AMA: 39-44 years old And/or~* DOR: AMH \< 1 \& FSH \>10 (age independent)~Exclusion Criteria:~* Contraindication for pregnancy~* Have not fulfilled requirements for IVF cycle~* Single gene couple or chromosomal rearrangement~* Severe male factor or testicular surgical sperm removal (need sufficient sperm for ICSI)~* One ovary~* Uterine anomalies~* Stage III or IV endometriosis~* Explained recurrent miscarriage~* PCO or PCOS~* Using donor oocyte or gestational carrier

- Gender: FEMALE
- Minimum Age: 26 Years
- Maximum Age: 44 Years
- Healthy Volunteers: t

Study Arms:
- Testing group (Type: EXPERIMENTAL): Timing of trigger at end of ovarian stimulation in an IVF cycle: trigger when 2 follicles reach 18mm, OR 1 follicle reaches 18mm AND 1 follicle is between 16-18mm.
- Control group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Evidence of a personally signed and dated informed consent document by the patient indicating that he/she (or a legally acceptable representative) has been informed of all pertinent aspects of the study is a requirement for inclusion.~* Additional inclusion criteria reflect the approved label for Thelin as outlined in the SmPC.~Exclusion Criteria:~* There are no specific exclusion criteria for enrollment in the Thelin Patient Safety Registry, with the exception of those reflected in the approved label for Thelin as outlined in the SmPC.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thelin Registry Patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Supination/Flexion Maneuver to Hyperpronation Maneuver

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of radial head subluxation~* No evidence of direct trauma to the arm~* No fracture in the arm~* No history of musculoskeletal disease~Exclusion Criteria:~-Refusing to participate in the study

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Supination-flexion (Type: ACTIVE_COMPARATOR): Supination-flexion maneuver will be applied in the treatment of patients in this group.
- Hyperpronation (Type: ACTIVE_COMPARATOR): Hyperpronation maneuver will be applied in the treatment of patients in this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Biologic Mesh vs Bioabsorbable Mesh During Ventral Hernia Repair in At-risk Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Grade II or III ventral hernia according to Ventral Hernia Working Group (VHWG)~* Pre-operative informed consent is obtainable~Exclusion Criteria:~* Return to the operating room within the next 1 year for additional open abdominal surgery is anticipated~* Absence of fascial defect or fascial defect less than 3 cm in greatest dimension~* Presence of previously place mesh (synthetic or biologic) at the site of surgery, which will not be completely removed and will, in part or whole, remain at the site of implantation of the study mesh~* Concurrent placement of another mesh (synthetic or biologic) at the site where the study mesh is placed~* Grade IV ventral hernia according to VHWG system~* ASA score IV or above~* Any disease or condition along with the surgeon's clinical judgment that contraindicates the use of either study mesh~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bio-A Arm (Type: EXPERIMENTAL): Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected.
- Strattice Arm (Type: ACTIVE_COMPARATOR): Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected..

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Clinical Study Evaluating Tibiofemoral Rotational Alignment Using Intraoperative Sensing During Total Knee Arthroplasty (TKA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who meet the indications for use for Triathlon® Total Knee System using VERASENSE™~* Subject must be diagnosed with one or more of the following conditions~* osteoarthritis~* rheumatoid or other inflammatory arthritis~* post-traumatic arthritis~* Subject is likely to be available for all study visits~* Subject is able and willing to sign the informed consent and follow study procedures~Exclusion Criteria:~* Prior Total Knee Arthroplasty~* Avascular Necrosis~* Any knee surgery other than meniscectomy (can be arthroscopic or open)~* Ligament insufficiencies, prior surgeries such as anterior cruciate ligament (ACL) or PCL reconstructions, posterolateral reconstructions, osteotomies, tibia plateau fractures~* Ipsilateral foot/ankle and hip arthritis~* Range of motion less than 90°, flexion contracture greater than 20°~* Subject has a mental condition that may interfere with the subject's ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the Subject cannot understand the informed consent process, global dementia, prior strokes that interfere with the Subject's cognitive abilities, senile dementia, and Alzheimer's Disease)~* Any subjects meeting any contraindication criteria as identified in the locally approved labeling for the device should be excluded from this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A TKA without VERASENSE (Type: SHAM_COMPARATOR): Patients who undergo primary posterior cruciate ligament (PCL)-retaining or - sacrificing TKA without the use of VERASENSE to guide rotational alignment and balance.
- Group B TKA with VERASENSE (Type: ACTIVE_COMPARATOR): Patients who undergo primary PCL-retaining or - sacrificing TKA with the use of VERASENSE to guide rotational alignment and balance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of bladder carcinoma (\>50% urothelial carcinoma)~* Prior treatment with at least one cycle of platin-based neoadjuvant chemotherapy~* Prior treatment with radical cystectomy revealing pT3NxM0 or pTanyN+M0~* ECOG performance status of 0-1 (Appendix 2).~* No evidence of metastases within 4 weeks of registration~* Adequate organ and marrow function obtained within 14 days of registration~Exclusion Criteria:~* Severe or uncontrolled acute or chronic medical or psychiatric condition~* Prior antiangiogenic therapy~* Prior pelvic radiation for bladder cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous Daily Dosing of Sunitinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues